Investor Presentation First Nine Months of 2022
105
Investor presentation First nine months of 2022
Novo NordiskⓇ
Potential first human dose with cell therapy in collaboration with
Heartseed and others
Utilise internal capabilities and disease understanding
for stem cell development
Accelerate innovation through partnerships
Internal capabilities
GMP-grade production
capability
my
Academic
collaborations
Ethical stem
cell practices
IP positions on
differentiation protocols
2 first human
dose projects
upcoming
Therapeutic areas
Heartseed
.
iPSC derived cardiomyocyte spheroids
for direct injection into heart
Parkinson's disease
Chronic heart
failure
LUND
Type 1
diabetes
UNIVERSITY
BioLamina
REVOLUTIONIZING CELL CULTURE
Dry age-related
macular degeneration
UCSF
University of California
San Francisco
hESC derived dopaminergic progenitor
neurons for placing into the brain
· Parkinson's disease
•
Novo Nordisk scientists embedded at UCSF lab
Process development, manufacturing, QA/QC,
facilities and operations at Fremont site
GMP: Good manufacturing practice; IP: Intellectual property; iPSC: induced pluripotent stem cells; QA/QC: Combination of quality assurance with quality assurance and quality control; hESC: Human embryonic stem cellView entire presentation